|
Schizophrenia
|
0.310 |
Biomarker
|
disease |
PSYGENET |
Our findings are the first to suggest that impairment of SHP-1 expression is involved in the physiopathology of schizophrenia, opening fruitful new avenues for ameliorating treatment at least of negative symptoms.
|
24793756 |
2014 |
|
Schizophrenia
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Our findings are the first to suggest that impairment of SHP-1 expression is involved in the physiopathology of schizophrenia, opening fruitful new avenues for ameliorating treatment at least of negative symptoms.
|
24793756 |
2014 |
|
Calcinosis
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Raloxifene attenuates Gas6 and apoptosis in experimental aortic valve disease in renal failure.
|
21335463 |
2011 |
|
Heart valve disease
|
0.300 |
Biomarker
|
group |
CTD_human |
Raloxifene attenuates Gas6 and apoptosis in experimental aortic valve disease in renal failure.
|
21335463 |
2011 |
|
Tumoral calcinosis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Raloxifene attenuates Gas6 and apoptosis in experimental aortic valve disease in renal failure.
|
21335463 |
2011 |
|
Microcalcification
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Raloxifene attenuates Gas6 and apoptosis in experimental aortic valve disease in renal failure.
|
21335463 |
2011 |
|
Respiratory Hypersensitivity
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Tyrosine phosphatase SHP-1 in oxidative stress and development of allergic airway inflammation.
|
18441283 |
2008 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We show that GroPIns4P is required for EGF-induced fibroblast migration and that it is part of a cPLA<sub>2</sub>/GroPIns4P/Shp1/Src cascade that might have broad implications for studies of immune-inflammatory response and cancer.
|
30823936 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The PTPN6 gene has been considered as a candidate tumor suppressor in hematological and solid malignancies, and promoter methylation may be an epigenetic modification silencing its expression.
|
30816454 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, in spite of decreased SHP1 levels in gammaherpesvirus-driven B cell lymphomas, B cell-intrinsic SHP1 expression plays a proviral role during the establishment of chronic infection, suggesting that the gammaherpesvirus-SHP1 interaction is more nuanced and is modified by the stage of infection and pathogenesis.<b>IMPORTANCE</b> Gammaherpesviruses establish lifelong infection in a majority of adults worldwide and are associated with a number of malignancies, including B cell lymphomas.
|
31597758 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Overexpression of miR-152 also increased the expression of tumor suppressor genes SOCS3 and SHP-1.
|
30470842 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumors expressing NTRK1-pY674/pY675 and low or undetectable levels of PTPN6 and TP53 were significantly associated with 5-year RFS (P = .014) when the dataset was stratified by MYCN amplification, segmental chromosomal abnormalities and histology.
|
30594749 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Aberrant hypermethylation of the P2 exhibited marked tumor specificity and was identified to be associated with the expression level of PTPN6.
|
30816454 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finding selective inhibitors for Shp2 is useful because although its inhibition is advantageous for the treatment of some types of cancer, inhibition of Shp1 may have the opposite effect, since it acts as a suppressor of tumors.
|
31268558 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> Overall, the study findings demonstrated that chrysin acts as a candidate for the treatment of HCC through modulating SHP-1/STAT3 signaling pathway.
|
31114345 |
2019 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our data suggest that PH inhibits STAT3 activity in Sor-sensitive and -resistant HCCs via SHP-1-mediated inhibition of STAT3 and AKT/mTOR/JAK2/VEGFR2 pathway.
|
31619257 |
2019 |
|
Myeloid Leukemia, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Corrigendum to "Apoptosis Induced by Tanshinone IIA and Cryptotanshinone Is Mediated by Distinct JAK/STAT3/5 and SHP1/2 Signaling in Chronic Myeloid Leukemia K562 Cells".
|
30622586 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the Ec group, SHP-1 immunoreactivity was correlated with grading, demonstrating that more differentiated lesions expressed SHP-1 more frequently than less differentiated neoplasms (G1 vs. G2, P=0.0243, statistically significant value, Fisher exact test; G1 vs. G3, P=0.0088, extremely significant value, Fisher exact test).
|
28187032 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Targeting the RNF6/SHP-1/STAT3 axis provides a potential therapeutic option for RNF6-amplified tumors.<i></i>.
|
29288235 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
IP injection of ATO significantly decreased the xenograft tumor volume and upregulated SHP-1 expression, which were attenuated by co-IP injection of pervanadate.
|
29409467 |
2018 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings suggest that regulation of the HNF1α/HNF1A-AS1/SHP-1 axis may have beneficial effects in the treatment of HCC.
|
29466992 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this present review, we will discuss the importance and function of SHP-1/p-STAT3 signaling in nonmalignant conditions as well as malignancies, its cross-talk with other pathways, the current clinical development and the potential role of inhibitors of this pathway in anticancer therapy and clinical relevance of SHP-1/p-STAT3 in cancers.
|
28594363 |
2017 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The methylation status of the Src homology 2 domain-containing tyrosine phosphatase 1 (SHP1) gene, a negative regulator of signal transduction, has been identified as being altered in numerous haematological malignancies.
|
28599500 |
2017 |
|
Myeloid Leukemia, Chronic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PTPN6 was down-regulated in cell lines and patients with advanced phase CML, whereas DNMT1, DNMT3A, MECP2, MBD2 and HDAC1 were up-regulated.
|
28480959 |
2017 |
|
Myeloid Leukemia, Chronic
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The results revealed that SHP1 gene methylation status was altered during the progression of CML.
|
28599500 |
2017 |